HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dual Anti-HER2 Therapy Reduces Recurrence Risk

December 13th 2019

A pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Guidelines Address Questions About Evaluating Less Common HER2 Testing Patterns

December 12th 2019

For the past 2 decades, clinical guidelines for the diagnosis and management of breast cancer have sought to clarify the definition of HER2 status, but several key questions remain.

Dr. Murthy on HER2CLIMB Trial Results in HER2+ Breast Cancer

December 12th 2019

Rashmi K. Murthy, MD, MBE, discusses results of the HER2CLIMB trial in previously treated HER2-positive breast cancer.

Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate

December 12th 2019

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer

December 12th 2019

Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.

Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer

December 12th 2019

Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.

Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent

December 12th 2019

Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer

December 11th 2019

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.

Dr. Hamilton on the KATHERINE Trial in HER2+ Breast Cancer

December 3rd 2019

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Exciting Advances Continue in HER2+ Breast Cancer and Other Subtypes

November 20th 2019

Kurt W. Tauer, MD, FACP, discusses encouraging updates across the spectrum of breast cancer subtypes.

Research Efforts in HER2+ Breast Cancer Focused on Optimizing Novel Agents

November 19th 2019

Gregory Vidal, MD, PhD, discussed the ways in which currently available and investigational agents are being evaluated in the curative and metastatic settings of HER2-positive breast cancer.

Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer

November 15th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 15th 2019

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Pivotal Data in HER2+ Breast Cancer Transform Paradigm

November 13th 2019

Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.

Dr. Gogineni on Implications of the APT Trial in HER2+ Breast Cancer

November 12th 2019

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

Dr. O'Regan on Prognostic Value of pCR in HER2+ Breast Cancer

November 9th 2019

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

Margetuximab Elicits Modest Survival Extension in HER2+ Breast Cancer

October 24th 2019

The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy.

Tucatinib Triplet Improves Survival in Advanced HER2+ Breast Cancer

October 21st 2019

Tucatinib combined with trastuzumab and capecitabine improved overall survival and progression-free survival compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast Cancer

October 21st 2019

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases

October 17th 2019

Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.